Wolfe Research Upgrades Intellia Therapeutics (NTLA) to Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts NTLA Hot Sheet
Price: $11.21 +0.45%
Rating Summary:
22 Buy, 9 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Rating Summary:
22 Buy, 9 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Join SI Premium – FREE
Wolfe Research analyst Andy Chen upgraded Intellia Therapeutics (NASDAQ: NTLA) from Peerperform to Outperform with a price target of $21.00.
For an analyst ratings summary and ratings history on Intellia Therapeutics click here. For more ratings news on Intellia Therapeutics click here.
Shares of Intellia Therapeutics closed at $7.23 yesterday.
You May Also Be Interested In
- Freedom Broker Upgrades Goldman Sachs (GS) to Buy
- WBB Securities Upgrades Turn Therapeutics (TTRX) to Hold
- BofA Securities Upgrades Pharvaris B.V. (PHVS) to Buy
Create E-mail Alert Related Categories
UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
